Latham & Watkins is advising Rhythm Pharmaceuticals on the transaction, and Ropes & Gray is advising Perceptive Advisors LLC. Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (Rhythm), a commercial-stage...
Rhythm Pharmaceuticals’ $150 Million Financing
Gurnet Point Capital’s Acquisition of Paratek Pharmaceuticals
Latham & Watkins advises Gurnet Point Capital in acquisition of Paratek Pharmaceuticals. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Vor Biopharma’s $115.8 Million Common Stock Offering and Private Placement
Latham & Watkins LLP represented the underwriters and placements agents in the transaction. Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced...
Intellia Therapeutics’ $300 Million Common Stock Offering
Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...
POINT Biopharma’s $125 Million Common Stock Offering
Latham & Watkins represented the underwriters in the offering. POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Precision BioSciences’ $50 Million Common Stock Offering
Latham & Watkins represented Precision BioSciences, Inc. in the offering. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Oscar Health’s $305 Million Convertible Senior Notes Offering
Latham & Watkins represented Oscar Health in the offering. Oscar Health, Inc., the first health insurance company built on a full stack technology platform, has announced a...
Agenus’ Launch of SaponiQx
Latham & Watkins represented Agenus Inc. in the transaction. Agenus Inc. (Agenus), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
Sight Sciences’ $240 Million Initial Public Offering
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
Senda Biosciences’ Collaboration with Nestlé Health Science
Latham & Watkins LLP represented Senda Biosciences in the transaction. Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field...